Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Viewray Inc (VRAY)

Viewray Inc (VRAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 839,956
  • Shares Outstanding, K 181,416
  • Annual Sales, $ 70,120 K
  • Annual Income, $ -110,050 K
  • 60-Month Beta 0.99
  • Price/Sales 12.37
  • Price/Cash Flow N/A
  • Price/Book 8.32
Trade VRAY with:

Options Overview Details

View History
  • Implied Volatility 51.12% ( -4.81%)
  • Historical Volatility 36.20%
  • IV Percentile 5%
  • IV Rank 14.52%
  • IV High 193.42% on 08/03/22
  • IV Low 26.94% on 09/09/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 63
  • Volume Avg (30-Day) 2,532
  • Put/Call OI Ratio 6.25
  • Today's Open Interest 266,367
  • Open Int (30-Day) 247,513

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.15
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.17
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.25 +7.18%
on 11/09/22
4.89 -6.85%
on 12/01/22
+0.13 (+3.05%)
since 11/04/22
3-Month
3.26 +39.72%
on 09/07/22
4.89 -6.85%
on 12/01/22
+1.30 (+40.15%)
since 09/06/22
52-Week
2.39 +90.59%
on 05/09/22
5.99 -23.96%
on 12/08/21
-0.34 (-6.85%)
since 12/06/21

Most Recent Stories

More News
ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced that it has entered into a new five-year loan facility agreement with MidCap...

VRAY : 4.56 (-1.51%)
ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake,...

VRAY : 4.56 (-1.51%)
ViewRay® to Present at the Stifel 2022 Healthcare Conference

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and...

VRAY : 4.56 (-1.51%)
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VRAY : 4.56 (-1.51%)
AORT : 12.97 (-2.41%)
ViewRay Announces Third Quarter 2022 Results

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third Quarter...

VRAY : 4.56 (-1.51%)
MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the final primary endpoint results from the phase III randomized single-center MIRAGE trial...

VRAY : 4.56 (-1.51%)
ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the findings from the first Phase II prospective international multi-institutional study to...

VRAY : 4.56 (-1.51%)
MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian® MRI-Guided Radiation Therapy System will be featured at the 64th...

VRAY : 4.56 (-1.51%)
ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the launch of a phase III randomized controlled trial titled "Locally Advanced Pancreatic cancer...

VRAY : 4.56 (-1.51%)
ViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of third quarter 2022 financial results. ViewRay will hold a...

VRAY : 4.56 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio.

See More

Key Turning Points

3rd Resistance Point 5.09
2nd Resistance Point 4.96
1st Resistance Point 4.80
Last Price 4.56
1st Support Level 4.51
2nd Support Level 4.38
3rd Support Level 4.22

See More

52-Week High 5.99
Fibonacci 61.8% 4.61
Last Price 4.56
Fibonacci 50% 4.19
Fibonacci 38.2% 3.77
52-Week Low 2.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar